Noninvasive Real-Time Characterization of Renal Clearance Kinetics in Diabetic Mice after Receiving Danshensu Treatment
Table 1
A summary of all measured variables collected from serum, urine, and MSOT in the present study.
Non-DM control
DM
DM ± DSS
Baseline measurement
Obesity
Body weight (g)
20.8 ± 0.69
51.79 ± 4.03
50.21 ± 3.08
Serum
Fasting glucose (mmol/l)
7.58 ± 0.60
23.83 ± 5.10
19.60 ± 3.58
After 3 weeks
Obesity
Body weight (g)
18.78 ± 1.21
56.52 ± 6.07
57.09 ± 4.03
Serum
Fasting glucose (mmol/l)
8.17 ± 1.36
24.24 ± 6.67
24.97 ± 6.32
Creatinine (μmol/l)
9.79 ± 1.37
14.90 ± 3.79
14.80 ± 3.10
Total bilirubin (μmol/l)
1.40 ± 0.21
1.50 ± 0.51
1.69 ± 0.32
Conjugated bilirubin (μmol/l)
0.35 ± 0.10
0.43 ± 0.11
0.41 ± 0.16
Unconjugated bilirubin (μmol/l)
1.02 ± 0.23
1.10 ± 0.58
1.33 ± 0.37
Urine
F2-isoprostane (ng/mg of creatinine)
15.82 ± 8.73#
24.46 ± 6.59
18.00 ± 6.39
Urinary albumin : creatinine ratio (mg/g of creatinine)
33.5 ± 14.86
115.7 ± 41.54
118.2 ± 47.31
MSOT
Tmax delay (s)
90.21 ± 14.93
142.97 ± 13.96
81.96 ± 19.51
All data presented as mean ± SD. denotes when this group is compared to the non-DM control group. # denotes when this group is compared to the DM group.
